Efficacy and safety of peficitinib in rheumatoid arthritis

Kaneko, Yuko

doi:10.1080/14397595.2020.1794103

Cited by 8 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[407][408][409][410] Peficitinib is a JAK3 inhibitor for treating RA recently approved in Japan. 411,412 Peficitinib attenuates RA symptoms and inhibits joint destruction in Japanese RA patients who do not respond adequately to MTX. 413,414 Iguratimod, which inhibits the activation of NF-κB, is a novel DMARDs approved for the treatment of RA in Japan and China.…”

Section: Approved Drugsmentioning

confidence: 99%

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Ding

Wang

et al. 2023

Sig Transduct Target Ther

112

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an incurable systemic autoimmune disease. Disease progression leads to joint deformity and associated loss of function, which significantly impacts the quality of life for sufferers and adds to losses in the labor force. In the past few decades, RA has attracted increased attention from researchers, the abnormal signaling pathways in RA are a very important research field in the diagnosis and treatment of RA, which provides important evidence for understanding this complex disease and developing novel RA-linked intervention targets. The current review intends to provide a comprehensive overview of RA, including a general introduction to the disease, historical events, epidemiology, risk factors, and pathological process, highlight the primary research progress of the disease and various signaling pathways and molecular mechanisms, including genetic factors, epigenetic factors, summarize the most recent developments in identifying novel signaling pathways in RA and new inhibitors for treating RA. therapeutic interventions including approved drugs, clinical drugs, pre-clinical drugs, and cutting-edge therapeutic technologies. These developments will hopefully drive progress in new strategically targeted therapies and hope to provide novel ideas for RA treatment options in the future.

show abstract

Section: Approved Drugsmentioning

confidence: 99%

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Ding

Wang

et al. 2023

Sig Transduct Target Ther

112

View full text Add to dashboard Cite

show abstract

“…The efficacy and safety of JAKis in rheumatic diseases, mainly RA in adults, as well as in RA-associated ILD, have been demonstrated in several clinical trials but also in real-world studies [21,[44][45][46][47][48]. A potential role for JAKis has also been proposed for the treatment of systemic sclerosis-associated ILD [49].…”

Section: Efficacy Of Jakis In Ild Associated With Rheumatic Diseasementioning

confidence: 99%

Janus Kinase Inhibitors and Interstitial Lung Disease Associated With Pediatric Rheumatic Diseases: An Unexplored Field

Sapountzi,

Fotis,

Kotanidou

et al. 2023

Cureus

View full text Add to dashboard Cite

Rheumatic diseases are often complicated by lung disease, commonly presenting as interstitial lung disease (ILD), with potentially detrimental consequences for patient survival. Although less frequent in pediatric patients, pulmonary involvement may be observed in almost all childhood-onset rheumatic conditions. The development of biological disease-modifying anti-rheumatic drugs has significantly improved clinical outcomes. However, disease remission is not always complete or long-lasting, and treatment may need to be discontinued due to adverse effects. A novel class of drugs, namely Janus kinase inhibitors (JAKis), has been proposed to provide a significant survival benefit for patients with rheumatic diseases. Despite the ample literature on the efficacy and safety of JAKis in rheumatic disease, only a few studies have investigated the effectiveness of these drugs in patients with pulmonary involvement, and only two case reports have presented results in pediatric patients. We provide an overview of the rationale for using JAKis in ILDs associated with rheumatic disease and summarize the main studies evaluating their efficacy in both adult and pediatric patients. The present review highlights the need for controlled long-term studies to assess the efficacy and safety of JAKis in pediatric rheumatic disease complicated by lung disease.

show abstract

“…In addition, no drop in the effectiveness of peficitinib was observed after long-term use [ 156 ]. However, the use of peficitinib was also associated with a risk of herpes zoster infection, similar to other JAK inhibitors [ 157 ].…”

Section: Introductionmentioning

confidence: 99%

A Comprehensive Overview of Globally Approved JAK Inhibitors

et al. 2022

View full text Add to dashboard Cite

Janus kinase (JAK) is a family of cytoplasmic non-receptor tyrosine kinases that includes four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling through the JAK-STAT pathway, which regulates the transcription of several genes involved in inflammatory, immune, and cancer conditions. Targeting the JAK family kinases with small-molecule inhibitors has proved to be effective in the treatment of different types of diseases. In the current review, eleven of the JAK inhibitors that received approval for clinical use have been discussed. These drugs are abrocitinib, baricitinib, delgocitinib, fedratinib, filgotinib, oclacitinib, pacritinib, peficitinib, ruxolitinib, tofacitinib, and upadacitinib. The aim of the current review was to provide an integrated overview of the chemical and pharmacological data of the globally approved JAK inhibitors. The synthetic routes of the eleven drugs were described. In addition, their inhibitory activities against different kinases and their pharmacological uses have also been explained. Moreover, their crystal structures with different kinases were summarized, with a primary focus on their binding modes and interactions. The proposed metabolic pathways and metabolites of these drugs were also illustrated. To sum up, the data in the current review could help in the design of new JAK inhibitors with potential therapeutic benefits in inflammatory and autoimmune diseases.

show abstract

Efficacy and safety of peficitinib in rheumatoid arthritis

Cited by 8 publications

References 30 publications

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Janus Kinase Inhibitors and Interstitial Lung Disease Associated With Pediatric Rheumatic Diseases: An Unexplored Field

A Comprehensive Overview of Globally Approved JAK Inhibitors

Contact Info

Product

Resources

About